SNMMI 2026

Join Dr. Gayatri Acharya from Cone Health as she shares practical insights from implementing and optimizing the StarGuide CZT SPECT/CT in a busy nuclear cardiology program. The presentation will explore workflow strategies, clinical performance, emerging CFR use, and how her team determines when CZT SPECT/CT versus PET/CT is the right choice for patients. Speakers(s): Gayatri Ajay Acharya, M.D., Moses H. Cone Memorial Hospital

This session reviews the SNMMI/EANM/ASNC/ACNM Procedure Standard/Practice Guideline for Flyrcado^TM (flurpiridaz F 18 injection) PET Myocardial Perfusion Imaging, highlighting the supporting evidence and key clinical recommendations. Join us as we translate guidance into real‑world practice by discussing technical, workflow, and operational considerations for implementing and scaling a cardiac PET program to drive meaningful clinical impact. Learning Objectives At the end of this session, participants will be able to:

1. Summarize key elements of the SNMMI/EANM/ASNC/ACNM procedure standard and practice guideline for F 18 flurpiridaz PET myocardial perfusion imaging.
2. Identify technical considerations required for high-quality cardiac PET imaging.
3. Describe operational and workflow strategies for implementing and optimizing a cardiac PET program in clinical practice.

  IMPORTANT SAFETY INFORMATION FLYRCADO™ (flurpiridaz F 18) injection, for intravenous use Indications and Usage FLYRCADO is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Contraindications  None Radiation Risks FLYRCADO contributes to cumulative radiation exposure, which is associated with an increased risk of cancer. Handle safely to minimize exposure for patients and staff. Advise patients to hydrate before and after administration and to void frequently. Adverse Reactions Most common adverse reactions (≥2%) include dyspnea, headache, angina pectoris, chest pain, fatigue, ST-segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. Use in Specific Populations Pregnancy: No human data are available. Counsel patients about potential fetal risks related to radiation and ethanol exposure (contains up to 337 mg anhydrous ethanol). Lactation: Advise women to pump and discard breast milk for at least 8 hours after administration. Pediatric Use: Safety and effectiveness have not been established. To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at GPV.drugsafety@gehealthcare.com or FDA at 800-FDA-1088 or www.fda.gov/medwatch Please see the full Prescribing Information for additional important safety information.  

Join GE HealthCare for a multidisciplinary panel discussion that explores how neurologists, radiologists and technologists work together to accelerate early and definitive diagnosis in neurodegenerative disease—highlighting real‑world challenging cases, the growing role of quantification in clarifying mixed or borderline pathology, and how an integrated imaging perspective strengthens diagnostic confidence to support clear decision‑making across complex presentations. Speaker(s): Lourdes Benes, M.D., Medical Director,  Neurology One Phillip Kuo, M.D., Ph.D., President of the SNMMI Brain Imaging Council Giuseppe Esposito, M.D., Chief of Nuclear Medicine and PET/CT and Professor of Radiology at Medstar Georgetown University Hospital Matthew Hulse, CNMT, Director of Nuclear Medicine and PET at SimonMed Imaging